The Medicines and Healthcare products Regulatory Agency (MHRA) regulates devices in Great Britain under the UK MDR 2002 (as amended). UKCA marking will replace CE marking for the GB market on a transition timeline currently extended through 2030 for many device classes. Great Britain (England, Scotland and Wales) uses the UK Medical Devices Regulations 2002, while Northern Ireland follows EU rules under the Windsor Framework. Devices must be registered with the MHRA, and non-UK manufacturers need a UK Responsible Person. Legislation allows CE-marked devices to continue to be placed on the Great Britain market until 2028 or 2030 depending on device type and certificate, while the UK finalizes its new framework.

Why it matters

Northern Ireland continues to follow EU rules under the Windsor Framework, requiring CE/UKNI marks. UK Approved Bodies - separate from EU Notified Bodies - perform conformity assessments for UKCA.

Common pitfalls

•Failing to understand the extended transition timelines for UKCA marking can lead to non-compliance for devices placed on the Great Britain market.
•Confusing the requirements for UKCA marking with CE marking, which applies in the EU and Northern Ireland, can result in incorrect conformity assessments.
•Not engaging with a UK Approved Body for higher-risk devices requiring third-party conformity assessment under UKCA regulations is a common pitfall.
•Assuming that a device with a CE mark can automatically be placed on the Great Britain market without considering any additional UKCA specific requirements, even during the transition period.
•Overlooking the specific requirements for economic operators, such as UK Responsible Persons, when marketing devices in Great Britain under UKCA regulations.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.